Compass Pathways Reports Positive Phase 3 Data for COMP360 in Treatment-Resistant Depression

Compass Pathways reported first-quarter 2026 financial results on Wednesday and held an earnings conference call to discuss progress on its COMP360 program. The company said it delivered positive data from both Phase 3 studies of COMP360 in treatment-resistant depression.

The trials, blinded for 26 weeks, along with earlier Phase 2b data, included more than 1,000 patients and comprehensive preclinical toxicology, safety and chemistry manufacturing control information. COMP360 demonstrated clinically meaningful efficacy with rapid onset and extended durability in patients with treatment-resistant depression.

The company stated that these results offer a profile not currently available from the single approved and used treatment for the condition. Kabir Nath, Chief Executive Officer, said the company began preparing for a potential accelerated launch after the first positive Phase 3 trial last year following discussions with the FDA.

The company has aligned with the FDA on a rolling submission and review plan and has begun submitting modules for the COMP360 new drug application. Part B data from the second Phase 3 trial is expected in early third quarter of 2026 and will complete the submission.

The company received a Commissioner's National Priority Voucher, which is intended to enable an accelerated review timeline of one to two months after final submission.

COMP360 is currently a Schedule I substance and will require rescheduling at both federal and state levels before it can be prescribed. Lori Engelbert, Chief Commercial Officer, said the company has worked at the state level for the past two years. Almost 90 percent of the U.S. population now lives in states that intend to reschedule COMP360 within 30 days after FDA approval and DEA rescheduling.

The company said it remains focused on being launch-ready by the end of 2026. It has established CPT Category III codes for providers to receive reimbursement for psychedelic monitoring and formed strategic collaborations across interventional psychiatry settings.

and Pipeline Expansion Compass

Pathways is building its commercial team and advancing commercial preparedness activities in anticipation of approval. The company is also progressing its program in post-traumatic stress disorder, which affects 13 million Americans, and has begun work with a contract research organization and trial sites for a late-stage PTSD study.

The company reported a strengthened balance sheet following a successful financing and warrant exercises in the first quarter. It said current cash reserves are expected to fund operations beyond launch and into 2028. Spravato (esketamine) is the only drug currently indicated and used for treatment-resistant depression.

It was treating less than 2 percent of the estimated 4 million treatment-resistant depression patients as of 2025 and is projected to reach $3 billion in revenue by 2027. The company stated that if approved, COMP360 could reach blockbuster status by providing a new treatment option for patients who have not responded to existing therapies.